SEQUENCE LISTING

<110> Robbins, Paul D.
      Frizzell, Raymond
      Mi, Zhibao
      Sun, Fei

<120> POLYPEPTIDES FOR INCREASING MUTANT CFTR
  CHANNEL ACTIVITY

<130> AP35301 072396.0261

<150> 60/407,461
<151> 2002-08-30

<160> 20

<170> FastSEQ for Windows Version 4.0

<210> 1
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> PTD-4

<400> 1
Pro Ile Arg Arg Arg Lys Lys Leu Arg Arg Leu Lys
 1   5   10

<210> 2
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> PTD-5

<400> 2
Arg Arg Gln Arg Arg Thr Ser Lys Leu Met Lys Arg
 1   5   10

<210> 3
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> TAT

<400> 3
Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg
 1   5   10

<210> 4
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Ant

<400> 4
Arg Gln Ile Lys Ile Trp Phe Gln Asn Arg Arg Met Lys Trp Lys Lys
 1   5   10   15

<210> 5
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> 4R

<400> 5
Arg Arg Arg Arg
 1

<210> 6
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> 6R

<400> 6
Arg Arg Arg Arg Arg Arg
 1   5

<210> 7
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> 8R

<400> 7
Arg Arg Arg Arg Arg Arg Arg Arg
 1   5

<210> 8
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> 10R

<400> 8
Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg
 1   5   10

<210> 9
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> 12R

<400> 9
Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg
 1   5   10

<210> 10
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> 4K

<400> 10
Lys Lys Lys Lys
 1

<210> 11
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> 6K

<400> 11
Lys Lys Lys Lys Lys Lys
 1   5

<210> 12
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> 8K

<400> 12
Lys Lys Lys Lys Lys Lys Lys Lys
 1   5

<210> 13

<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> 10K

<400> 13
Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys
 1   5   10

<210> 14
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> 12K

<400> 14
Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys
 1   5   10

<210> 15
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> 5RQ

<400> 15
Arg Arg Gln Arg Arg
 1   5

<210> 16
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> 8RQ

<400> 16
Arg Arg Gln Arg Arg Gln Arg Arg
 1   5

<210> 17
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> 11RQ

<400> 17
Arg Arg Gln Arg Arg Gln Arg Arg Gln Arg Arg
 1   5   10

<210> 18
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> control, Con P

<400> 18
Ala Arg Pro Leu Glu His Gly Ser Asp Lys Ala Thr
 1   5   10

<210> 19
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> AWP-1

<400> 19
Thr Leu Pro Ser Pro Leu Ala Leu Leu Thr Val His
 1   5   10

<210> 20
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> ACP-1

<400> 20
Asp Pro Ala Thr Asn Pro Gly Pro His Phe Pro Arg
 1   5   10